Home > Result Summaries: Compounds > naratriptan > Result Summary for S2W40031

Result Summary for S2W40031

Result Summary

Protocol ID:	S2W40031
Clinical Study ID:	S2W40031(NARF4011)
Official Title:	A double-blind, randomised, parallel-group design, placebo-controlled study of the effects of naratriptan tablets 2.5mg in treatment of menstrually-associated migraine attack at a stage of mild pain.
Phase:	Phase 3
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C, and The French Naramig Collaborative Study Group. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol 2005; 12: 1-8.